Multiple Myeloma Treatments: World Drug Industry and Market 2013-2023

LONDON, November 1, 2013 /PRNewswire/ --

Myeloma medicines - now discover R&D trends, opportunities, and potential revenues

What are the commercial prospects for treating multiple myeloma? Visiongain's updated report gives you predictions, helping you stay ahead. There you see financial results, technological developments, opportunities, and commercial outlooks.

In that new analysis you discover sales forecasts to 2023 at overall world market, submarket, product, and national level for those drugs. You also assess technologies, competition, and progress for treating that cancer. There find data and potentials.

Read on to explore those products and see what their future market could be worth.

Forecasts to 2023 and other information to benefit your research and analysis

Besides revenue predictions to 2023, our report gives you recent results, growth rates, and market shares. There you discover original analysis, seeing outlooks for business and developments (R&D). You also get 64 tables, 57 charts, and two interviews.

Assessment of that medical industry, showing data you need

In that study you hear what's happening for those anti-cancer medicines, learning where needs and money lie. Now see how you and your organisation can gain.

Avoid falling behind or losing influence. Instead discover information you need to stay ahead. Our study assesses those pharmaceuticals for blood cancers (haematological malignancies), helping you save time and benefit your research, analyses, and decisions.

The following sections show, then, what you get in that new investigation.

Forecasting of the world market and segments for that cancer therapy

Discover in our report overall world drug revenue to 2023 for multiple myeloma. You also see individual revenue predictions for five therapeutic submarkets at world level:
• Immunomodulators
• Proteasome inhibitors
• Monoclonal antibodies (mAbs)
• Kinase inhibitors
• Other agents.

How will sales of those therapies expand? Which drug classes will generate most money? There you assess prospects for revenue growth, seeing where you can benefit from the treatment of multiple myeloma (plasma cell myeloma or Kahler's disease).

You also discover forecasts by agent, seeing how they can succeed.

Predictions for myeloma-treating products - find what revenues are possible

How will those cancer-treating drugs perform to 2023 at world level? Our study forecasts myeloma sales of six top brands and four expected medicines, including these:
• Revlimid
• Velcade
• Thalomid
• Zometa
• Pomalyst
• Elotuzumab.

There you find each agent's potential. You see what's happening, then, understanding challenges, trends, competitors, and opportunities.

You also find geographical predictions.

National markets - where will highest revenues and sales growth occur?

In developed and developing countries, multiple myeloma therapies will give opportunities to pharmaceutical companies. You see where and how, from 2013, understanding potentials.

In our report you find individual revenue forecasts to 2023 for 11 national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC countries - Brazil, Russia, India, and China.

There you find countries with highest revenues and predicted sales growth. Our work explains. Discover the future of those products, hearing about progress in that healthcare field and seeing what it means.

There you assess trends in oncology and tackling those diseases.

Issues affecting developers, producers, and sellers of myeloma-treating medicines

Our study explains forces affecting that industry and market from 2013, including these:
• Therapy by induction, maintenance, and salvage methods
• Research and development (R&D) for those blood and bone marrow disorders
• Governmental support for developing and marketing therapies
• Prospects and capabilities of companies investigating that oncology.

There you assess developments, finding advances and outlooks for business. Discover what the present and future hold.

Companies and overall 2017 market value - how high can its revenues go?

From 2013, myeloma treatments hold potential for investments, medical advances, and higher revenues. Our analysis predicts that overall world market will reach $11.5bn in 2017, expanding to 2023.

That work shows you what technologies and organisations hold greatest potential. In particular, you explore these companies:
• Celgene
• Johnson & Johnson (J&J)
• Takeda
• Novartis
• Bristol-Myers Squibb
• Onyx Pharmaceuticals.

See what's possible for that industry. Our investigation explains the potential of its market, helping you stay ahead.

Information found nowhere else - discover the future of those cancer-treating drugs

Through knowledge such as this, our report helps you get recognition for insight:
• Revenues to 2023 at world level, with forecasting of 5 submarkets, and 10 products - investigate prospects for investments and revenues
• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - assess countries for therapeutic needs, business, and expected sales growth
• Prospects for companies - explore portfolios, results, R&D, and outlooks.

Multiple Myeloma Treatments: World Drug Industry and Market 2013-2023 gives independent analysis. There you receive competitive intelligence found only in our work.

That new study helps you find the money and show your authority on that technology. Gain now by trying that report.

Anti-myeloma agents - find commercial potentials by ordering now

Our new report is for everyone investigating cancer of plasma cells (haematological malignancy) and its treatment market. There you discover revenue forecasts to 2023, with discussions of those technologies. Avoid missing out - please order now.

Companies Listed

AB Science
Abbott Laboratories
AbbVie
Abramsom Cancer Centre
Abraxis
Actavis
Allos Therapeutics
Amgen
Anthrogenesis
Arno Therapeutics
Array Biopharma
Astellas
Astex Pharmaceuticals
AstraZeneca
Bayer
Biogen Idec
Biotest Pharmaceuticals
Bristol-Myers Squibb
Broad Institute
Cancer Research UK
Celanese
Celgene
Cell Genesys
Celldex Therapeutics
Cephalon
Constellation Pharmaceuticals
Cougar Biotechnology
Dana-Farber Cancer Institute
Dr. Reddy's Laboratories
Eli Lilly
Emcure Pharmaceuticals
Entremed
EntreMed
Epizyme
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Galapagos
Genentech
Genmab
Geron Corporation
GlaxoSmithKline (GSK)
Gliknik
Gloucester Pharmaceuticals
Harvard Medical School
Hospira
Human Genome Sciences
Immune System Therapeutics
ImmunoGen
Immunomedics
Janssen Biotech
Jerome Lipper Centre for Multiple Myeloma
Johnson & Johnson
Karyopharm Therapeutics
Kyowa Hakko Kirin Pharma
Kyowa Hakko Kirin Pharma
Leukosite
Lipomed
MD Anderson Cancer Centre
Merck & Co.
Millennium Pharmaceuticals
MorphoSys
Multiple Myeloma Research Consortium
Multiple Myeloma Research Foundation
Mylan
Myogenics/ ProScript
Natco Pharma
National Institute for Health and Care Excellence (NICE)
Nereus Pharmaceuticals
Novartis
Oncolytics
OncoPep
Oncopeptides
Oncovir
Onyx Pharmaceuticals
Otsuka America Pharmaceutical
PDL BioPharma
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmacyclics
PharmaMar
Pharmion
Pharmion
Roche
Rockefeller University
Seattle Genetics
Senesco Technologies
Signal Pharmaceuticals
Sun Pharma Global
Synta Pharmaceuticals
Takeda
Teva Pharmaceuticals
The World Health Organization (WHO)
Threshold Pharmaceuticals
Translational Genomics Research Institute
University of Arkansas
University of Illinois
US National Comprehensive Cancer Network
Watson Pharmaceuticals

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com, Tel: +44(0)20-7336-6100

Or click on http://www.visiongain.com/Report/1120/The-All-Natural-Food-and-Drink-Market-2013-2023